Pharmaceutical Executive, March 2022 Issue (PDF)
Articles in this issue
Pressed Into Action: Measuring Pharma’s Reputation Reversal
Biopharma in 2021: Big Gains, Volatile Values
The Resilience of R&D: Pharma Posted Record Output in 2021
A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip
New Age of Psychedelics
Roads Less Traveled
Biopharma Stocks, M&A Sputter Amid More Headwinds
Pandemic Accelerates CTV Ascent: How Pharma Can Benefit
The Human Factor in Data Security Breaches
Tapping the Surge in Useful Contingent Labor Market
Aligning the Many Interpretations of ‘Unmet Medical Need’
Califf Has Rare Chance to Rewrite His Legacy
Pharmaceutical Executive, March 2022 Issue (PDF)
A Rocky Road Ahead for New FDA Chief Califf
Recent Videos
Related Content
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Podcast
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
